{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:35:17Z","timestamp":1779248117337,"version":"3.51.4"},"reference-count":90,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.beem.2025.101998","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T19:39:02Z","timestamp":1744918742000},"page":"101998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Growth hormone replacement therapy in childhood-onset craniopharyngioma"],"prefix":"10.1016","volume":"39","author":[{"given":"Laura","family":"van Iersel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiska","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanneke M.","family":"van Santen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.beem.2025.101998_bib1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1215\/15228517-2008-097","article-title":"Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England","volume":"11","author":"Arora","year":"2009","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.beem.2025.101998_bib2","unstructured":"Gan, H.W., et al., Pituitary and Hypothalamic Tumor Syndromes in Childhood. 2000."},{"issue":"3","key":"10.1016\/j.beem.2025.101998_bib3","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s11060-011-0540-6","article-title":"Incidence of craniopharyngioma in Denmark (n = 189) and estimated world incidence of craniopharyngioma in children and adults","volume":"104","author":"Nielsen","year":"2011","journal-title":"J Neurooncol"},{"issue":"7","key":"10.1016\/j.beem.2025.101998_bib4","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1210\/jc.2003-031751","article-title":"Longitudinal study on growth and body mass index before and after diagnosis of childhood craniopharyngioma","volume":"89","author":"Muller","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2025.101998_bib5","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2265.2005.02231.x","article-title":"Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up","volume":"62","author":"Karavitaki","year":"2005","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2025.101998_bib6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000507702","article-title":"Prevalence of endocrine and metabolic comorbidities in a national cohort of patients with craniopharyngioma","volume":"93","author":"Jazbinsek","year":"2020","journal-title":"Horm Res Paediatr"},{"issue":"10","key":"10.1016\/j.beem.2025.101998_bib7","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1159\/000531226","article-title":"Safety of growth hormone replacement therapy in childhood-onset craniopharyngioma: a systematic review and Cohort Study","volume":"113","author":"van Schaik","year":"2023","journal-title":"Neuroendocrinology"},{"issue":"9-10","key":"10.1016\/j.beem.2025.101998_bib8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1159\/000504512","article-title":"The diagnosis and treatment of Craniopharyngioma","volume":"110","author":"Muller","year":"2020","journal-title":"Neuroendocrinology"},{"issue":"6","key":"10.1016\/j.beem.2025.101998_bib9","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1530\/EJE-17-0044","article-title":"Very long-term sequelae of craniopharyngioma","volume":"176","author":"Wijnen","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2025.101998_bib10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1530\/EJE-16-0812","article-title":"The neuroendocrine sequelae of paediatric craniopharyngioma: a 40-year meta-data analysis of 185 cases from three UK centres","volume":"176","author":"Tan","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2025.101998_bib11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1210\/endrev\/bnac035","article-title":"Contemporary biological insights and clinical management of Craniopharyngioma","volume":"44","author":"Apps","year":"2023","journal-title":"Endocr Rev"},{"issue":"2","key":"10.1016\/j.beem.2025.101998_bib12","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s12020-017-1489-9","article-title":"Quality of life and growth after childhood craniopharyngioma: results of the multinational trial KRANIOPHARYNGEOM 2007","volume":"59","author":"Heinks","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2025.101998_bib13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.wneu.2022.05.038","article-title":"Quality of life in Craniopharyngioma: a systematic review","volume":"164","author":"Castle-Kirszbaum","year":"2022","journal-title":"World Neurosurg"},{"issue":"5","key":"10.1016\/j.beem.2025.101998_bib14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1530\/EJE-18-0505","article-title":"Long-term effects of growth hormone replacement therapy in childhood-onset Craniopharyngioma: results of the German Craniopharyngioma Registry (HIT-Endo)","volume":"179","author":"Boekhoff","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2025.101998_bib15","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1210\/jc.2015-1002","article-title":"Risk of neoplasia in pediatric patients receiving growth hormone therapy--a report from the pediatric endocrine society drug and therapeutics committee","volume":"100","author":"Raman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"9418","key":"10.1016\/j.beem.2025.101998_bib16","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/S0140-6736(04)16044-3","article-title":"Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis","volume":"363","author":"Renehan","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.beem.2025.101998_bib17","doi-asserted-by":"crossref","first-page":"P35","DOI":"10.1530\/EJE-21-1186","article-title":"Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement","volume":"186","author":"Boguszewski","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2025.101998_bib18","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s11102-021-01173-0","article-title":"Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors-a review of research and clinical practice","volume":"24","author":"Boguszewski","year":"2021","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.beem.2025.101998_bib19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1067\/S0022-3476(03)00246-4","article-title":"Update of guidelines for the use of growth hormone in children: the Lawson Wilkins pediatric endocrinology society drug and therapeutics committee","volume":"143","author":"Wilson","year":"2003","journal-title":"J Pedia"},{"issue":"4","key":"10.1016\/j.beem.2025.101998_bib20","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3171\/2016.4.PEDS16112","article-title":"Physiological growth hormone replacement and rate of recurrence of craniopharyngioma: the Genentech National Cooperative Growth Study","volume":"18","author":"Smith","year":"2016","journal-title":"J Neurosurg Pedia"},{"issue":"11","key":"10.1016\/j.beem.2025.101998_bib21","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1210\/jc.2004-0667","article-title":"Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of KIGS (Pfizer International Growth Database)","volume":"89","author":"Geffner","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2025.101998_bib22","doi-asserted-by":"crossref","first-page":"e1397","DOI":"10.1210\/clinem\/dgz279","article-title":"Fractures, bone mineral density, and final height in craniopharyngioma patients with a follow-up of 16 years","volume":"105","author":"van Santen","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2025.101998_bib23","first-page":"91","article-title":"Efficacy and safety of growth hormone treatment in children with prior craniopharyngioma: an analysis of the Pharmacia and Upjohn International Growth Database (KIGS) from 1988 to 1996","volume":"49","author":"Price","year":"1998","journal-title":"Horm Res"},{"issue":"11","key":"10.1016\/j.beem.2025.101998_bib24","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1210\/jc.2019-00539","article-title":"Clinical importance of free thyroxine concentration decline after radiotherapy for pediatric and adolescent brain tumors","volume":"104","author":"van Iersel","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2025.101998_bib25","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1210\/endrev\/bnab040","article-title":"Hypothalamic-pituitary and other endocrine surveillance among childhood cancer survivors","volume":"43","author":"van Iersel","year":"2022","journal-title":"Endocr Rev"},{"issue":"3","key":"10.1016\/j.beem.2025.101998_bib26","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0889-8529(05)70345-5","article-title":"The growth without growth hormone syndrome","volume":"25","author":"Geffner","year":"1996","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"2","key":"10.1016\/j.beem.2025.101998_bib27","first-page":"374","article-title":"Replacement of growth hormone (GH) in normally growing GH-deficient patients operated for craniopharyngioma","volume":"80","author":"Schoenle","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2025.101998_bib28","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1055\/s-2001-16855","article-title":"Obesity after childhood craniopharyngioma--German multicenter study on pre-operative risk factors and quality of life","volume":"213","author":"Muller","year":"2001","journal-title":"Klin Padiatr"},{"issue":"5","key":"10.1016\/j.beem.2025.101998_bib29","article-title":"The development of hypothalamic obesity in craniopharyngioma patients: a risk factor analysis in a well-defined cohort","volume":"65","author":"van Iersel","year":"2018","journal-title":"Pedia Blood Cancer"},{"issue":"1","key":"10.1016\/j.beem.2025.101998_bib30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1210\/er.2018-00017","article-title":"Pathophysiology and individualized treatment of hypothalamic obesity following Craniopharyngioma and other suprasellar tumors: a systematic review","volume":"40","author":"van Iersel","year":"2019","journal-title":"Endocr Rev"},{"issue":"7","key":"10.1016\/j.beem.2025.101998_bib31","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/neuonc\/nov044","article-title":"Survival, hypothalamic obesity, and neuropsychological\/psychosocial status after childhood-onset craniopharyngioma: newly reported long-term outcomes","volume":"17","author":"Sterkenburg","year":"2015","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.beem.2025.101998_bib32","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1210\/jc.2014-3525","article-title":"Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden","volume":"100","author":"Olsson","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2025.101998_bib33","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1530\/EJE-15-0422","article-title":"Nonalcoholic fatty liver disease and fatigue in long-term survivors of childhood-onset craniopharyngioma","volume":"173","author":"Hoffmann","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2025.101998_bib34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11102-012-0428-2","article-title":"Mortality and morbidity in adult craniopharyngioma","volume":"16","author":"Erfurth","year":"2013","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.beem.2025.101998_bib35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1530\/EJE-17-0387","article-title":"The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up","volume":"178","author":"Wijnen","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2025.101998_bib36","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2265.2009.03639.x","article-title":"Insulin sensitivity and secretion in children and adolescents with hypothalamic obesity following treatment for craniopharyngioma","volume":"72","author":"Simoneau-Roy","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"10.1016\/j.beem.2025.101998_bib37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1210\/jc.2003-030442","article-title":"Features of the metabolic syndrome after childhood craniopharyngioma","volume":"89","author":"Srinivasan","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2025.101998_bib38","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2147\/DMSO.S425399","article-title":"Blood lipid disorders in post-operative craniopharyngioma children and adolescents and the improvement with recombinant human growth hormone replacement","volume":"16","author":"Du","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"5","key":"10.1016\/j.beem.2025.101998_bib39","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1515\/jpem-2022-0605","article-title":"Benefits and risks evaluation of recombinant human growth hormone replacement therapy in children with GHD after craniopharyngioma surgery","volume":"36","author":"Pei","year":"2023","journal-title":"J Pedia Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2025.101998_bib40","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1530\/EJE-13-0280","article-title":"Clinical characteristics and effects of GH replacement therapy in adults with childhood-onset craniopharyngioma compared with those in adults with other causes of childhood-onset hypothalamic-pituitary dysfunction","volume":"169","author":"Yuen","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1016\/j.beem.2025.101998_bib41","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1210\/jc.2005-0185","volume":"90","author":"Verhelst","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2025.101998_bib42","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1210\/jc.2017-01542","article-title":"Relative risks of contributing factors to morbidity and mortality in adults with Craniopharyngioma on growth hormone replacement","volume":"103","author":"Yuen","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2025.101998_bib43","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40618-014-0196-0","article-title":"Analysis of short- and long-term metabolic effects of growth hormone replacement therapy in adult patients with craniopharyngioma and non-functioning pituitary adenoma","volume":"38","author":"Profka","year":"2015","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"10.1016\/j.beem.2025.101998_bib44","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1530\/EJE-09-0449","article-title":"Hypothalamic involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on long-term GH therapy","volume":"161","author":"Holmer","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2025.101998_bib45","doi-asserted-by":"crossref","first-page":"w14521","DOI":"10.4414\/smw.2018.14521","article-title":"A ten-year follow-up study of treatment outcome of craniopharyngiomas","volume":"148","author":"Andereggen","year":"2018","journal-title":"Swiss Med Wkly"},{"issue":"2","key":"10.1016\/j.beem.2025.101998_bib46","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1359\/jbmr.2001.16.2.398","article-title":"The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density","volume":"16","author":"Wuster","year":"2001","journal-title":"J Bone Min Res"},{"issue":"5","key":"10.1016\/j.beem.2025.101998_bib47","first-page":"207","article-title":"Long-term effects of growth hormone therapy on bone mineral density, body composition, and serum lipid levels in growth hormone deficient children: a 6-year follow-up study","volume":"58","author":"van der Sluis","year":"2002","journal-title":"Horm Res"},{"issue":"6","key":"10.1016\/j.beem.2025.101998_bib48","first-page":"364","article-title":"Bone mineral density and body composition in adolescents with childhood-onset growth hormone deficiency","volume":"71","author":"Boot","year":"2009","journal-title":"Horm Res"},{"issue":"4","key":"10.1016\/j.beem.2025.101998_bib49","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1210\/jc.2002-021541","article-title":"The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth","volume":"88","author":"Drake","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.beem.2025.101998_bib50","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa607","article-title":"Body composition and bone mineral density in Craniopharyngioma patients: a longitudinal study over 10 years","volume":"105","author":"van Santen","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2025.101998_bib51","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1530\/eje.1.01877","article-title":"The clinical, metabolic and endocrine features and the quality of life in adults with childhood-onset craniopharyngioma compared with adult-onset craniopharyngioma","volume":"152","author":"Kendall-Taylor","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2025.101998_bib52","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1469-8749.2004.tb00476.x","article-title":"Outcome of craniopharyngioma in children: long-term complications and quality of life","volume":"46","author":"Poretti","year":"2004","journal-title":"Dev Med Child Neurol"},{"issue":"8","key":"10.1016\/j.beem.2025.101998_bib53","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1210\/jc.2013-2000","article-title":"Hypothalamic involvement predicts cognitive performance and psychosocial health in long-term survivors of childhood craniopharyngioma","volume":"98","author":"Fjalldal","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2025.101998_bib54","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1530\/eje.1.02114","article-title":"Quality of life in treated adult craniopharyngioma patients","volume":"154","author":"Dekkers","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.beem.2025.101998_bib55","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00381-004-1124-y","article-title":"Longitudinal study on quality of life in 102 survivors of childhood craniopharyngioma","volume":"21","author":"Muller","year":"2005","journal-title":"Childs Nerv Syst"},{"issue":"3","key":"10.1016\/j.beem.2025.101998_bib56","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1365-2265.2002.01608.x","article-title":"The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults","volume":"57","author":"Gilchrist","year":"2002","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2025.101998_bib57","first-page":"15","article-title":"Health related quality of life and psychological outcome in patients treated for craniopharyngioma in childhood","volume":"19","author":"Pedreira","year":"2006","journal-title":"J Pedia Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.beem.2025.101998_bib58","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-22-0402","article-title":"Cancer in growth hormone excess and growth hormone deficit","volume":"30","author":"Guevara-Aguirre","year":"2023","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.beem.2025.101998_bib59","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrendo.2018.22","article-title":"Growth hormone - past, present and future","volume":"14","author":"Ranke","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2025.101998_bib60","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11357-017-9966-x","article-title":"The GH\/IGF-1 axis in a critical period early in life determines cellular DNA repair capacity by altering transcriptional regulation of DNA repair-related genes: implications for the developmental origins of cancer","volume":"39","author":"Podlutsky","year":"2017","journal-title":"Geroscience"},{"issue":"46","key":"10.1016\/j.beem.2025.101998_bib61","doi-asserted-by":"crossref","first-page":"81098","DOI":"10.18632\/oncotarget.19186","article-title":"Serum insulin-like growth factor-1 and its binding protein 3 as prognostic factors for the incidence, progression, and outcome of hepatocellular carcinoma: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.beem.2025.101998_bib62","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1365-2265.2005.02404.x","article-title":"Does growth hormone cause cancer?","volume":"64","author":"Jenkins","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.beem.2025.101998_bib63","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1530\/EJE-10-0859","article-title":"Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies","volume":"164","author":"Steuerman","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2025.101998_bib64","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ghir.2020.02.004","article-title":"Growth hormone receptor deficiency in humans associates to obesity, increased body fat percentage, a healthy brain and a coordinated insulin sensitivity","volume":"51","author":"Guevara-Aguirre","year":"2020","journal-title":"Growth Horm IGF Res"},{"issue":"3","key":"10.1016\/j.beem.2025.101998_bib65","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1227\/01.NEU.0000372918.68453.5B","article-title":"Hormone receptor expression in craniopharyngiomas: a clinicopathological correlation","volume":"67","author":"Hofmann","year":"2010","journal-title":"Neurosurgery"},{"issue":"1","key":"10.1016\/j.beem.2025.101998_bib66","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jocn.2012.04.014","article-title":"Craniopharyngioma cell growth is promoted by growth hormone (GH) and is inhibited by tamoxifen: involvement of growth hormone receptor (GHR) and IGF-1 receptor (IGF-1R)","volume":"20","author":"Li","year":"2013","journal-title":"J Clin Neurosci"},{"issue":"1","key":"10.1016\/j.beem.2025.101998_bib67","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41572-019-0125-9","article-title":"Craniopharyngioma","volume":"5","author":"Muller","year":"2019","journal-title":"Nat Rev Dis Prim"},{"issue":"6","key":"10.1016\/j.beem.2025.101998_bib68","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1046\/j.1365-2265.1999.00695.x","article-title":"GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety","volume":"50","author":"Abs","year":"1999","journal-title":"Clin Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2025.101998_bib69","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1530\/EJE-14-1123","article-title":"Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the hypopituitary control and complications study","volume":"172","author":"Child","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"10.1016\/j.beem.2025.101998_bib70","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1080\/08035250600577889","article-title":"Recurrence of brain tumours in patients treated with growth hormone: analysis of KIGS (Pfizer International Growth Database)","volume":"95","author":"Darendeliler","year":"2006","journal-title":"Acta Paediatr"},{"issue":"5 Pt 2","key":"10.1016\/j.beem.2025.101998_bib71","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0022-3476(96)70002-1","article-title":"Brain tumor recurrence in children treated with growth hormone: the National Cooperative Growth Study experience","volume":"128","author":"Moshang","year":"1996","journal-title":"J Pedia"},{"key":"10.1016\/j.beem.2025.101998_bib72","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.wneu.2017.09.164","article-title":"Physiologic growth hormone-replacement therapy and craniopharyngioma recurrence in pediatric patients: a meta-analysis","volume":"109","author":"Alotaibi","year":"2018","journal-title":"World Neurosurg"},{"issue":"9","key":"10.1016\/j.beem.2025.101998_bib73","first-page":"935","article-title":"Growth hormone therapy and the risk of tumor recurrence after brain tumor treatment in children","volume":"23","author":"Rohrer","year":"2010","journal-title":"J Pedia Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2025.101998_bib74","doi-asserted-by":"crossref","first-page":"e1020","DOI":"10.1210\/clinem\/dgab784","article-title":"Management of childhood-onset craniopharyngioma in Italy: a multicenter, 7-year follow-up study of 145 patients","volume":"107","author":"Zucchini","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2025.101998_bib75","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000284358","article-title":"Analyses of treatment variables for patients with childhood craniopharyngioma--results of the multicenter prospective trial KRANIOPHARYNGEOM 2000 after three years of follow-up","volume":"73","author":"Muller","year":"2010","journal-title":"Horm Res Paediatr"},{"issue":"8","key":"10.1016\/j.beem.2025.101998_bib76","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/clinem\/dgad079","article-title":"GH and childhood-onset Craniopharyngioma: when to initiate GH replacement therapy?","volume":"108","author":"Nguyen Quoc","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2025.101998_bib77","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1530\/EJE-12-0077","article-title":"Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up","volume":"166","author":"Olsson","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2025.101998_bib78","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa089","article-title":"Growth hormone therapy does not increase the risk of Craniopharyngioma and nonfunctioning pituitary adenoma recurrence","volume":"105","author":"Losa","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2025.101998_bib79","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1530\/EJE-17-0707","article-title":"Excess morbidity and mortality in patients with craniopharyngioma: a hospital-based retrospective cohort study","volume":"178","author":"Wijnen","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2025.101998_bib80","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1530\/EJE-11-1084","article-title":"Mortality and socioeconomic status in adults with childhood onset GH deficiency (GHD) is highly dependent on the primary cause of GHD","volume":"167","author":"Stochholm","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1016\/j.beem.2025.101998_bib81","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S2213-8587(20)30163-7","article-title":"Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study","volume":"8","author":"Savendahl","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2025.101998_bib82","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1210\/jc.2009-0178","article-title":"Long-term safety of recombinant human growth hormone in children","volume":"95","author":"Bell","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2025.101998_bib83","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2010.02.028","article-title":"Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database)","volume":"157","author":"Wilton","year":"2010","journal-title":"J Pedia"},{"issue":"5","key":"10.1016\/j.beem.2025.101998_bib84","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1210\/jc.2016-2046","article-title":"Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study","volume":"102","author":"Swerdlow","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.beem.2025.101998_bib85","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1590\/S0004-27302011000800009","article-title":"Adverse effects of growth hormone replacement therapy in children","volume":"55","author":"Souza","year":"2011","journal-title":"Arq Bras Endocrinol Metab"},{"key":"10.1016\/j.beem.2025.101998_bib86","first-page":"41","article-title":"Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database","volume":"68","author":"Darendeliler","year":"2007","journal-title":"Horm Res"},{"key":"10.1016\/j.beem.2025.101998_bib87","doi-asserted-by":"crossref","first-page":"1254231","DOI":"10.3389\/fped.2023.1254231","article-title":"Long acting growth hormone (LAGH), an update","volume":"11","author":"Grillo","year":"2023","journal-title":"Front Pedia"},{"key":"10.1016\/j.beem.2025.101998_bib88","article-title":"Usefulness and potential pitfalls of long-acting growth hormone analogs","volume":"12","author":"Yuen","year":"2021","journal-title":"Front Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2025.101998_bib89","doi-asserted-by":"crossref","first-page":"e2121","DOI":"10.1210\/clinem\/dgz149","article-title":"Long-acting growth hormone preparations - current status and future considerations","volume":"105","author":"Miller","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.beem.2025.101998_bib90","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1210\/jc.2018-01175","article-title":"Hypothalamic-pituitary and growth disorders in survivors of childhood cancer: an Endocrine Society Clinical Practice Guideline","volume":"103","author":"Sklar","year":"2018","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X25000314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X25000314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:35:27Z","timestamp":1760542527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X25000314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1521690X25000314"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2025.101998","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Growth hormone replacement therapy in childhood-onset craniopharyngioma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2025.101998","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101998"}}